Cargando…

Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines

Mechanically ventilated patients suffering critical illness are at high risk of developing neurocognitive impairments. Angiotensin type 2 receptor (AGTR2) has been demonstrated to be anti-inflammatory and neuroprotective. The present study thus aimed to investigate whether AGTR2 can alleviate cerebr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Liang, Chen, Dan-yang, Lou, Qian-qian, Cao, Peng, Hu, Rui, Jin, Yan, Wang, Di, Hu, Shan-shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734469/
https://www.ncbi.nlm.nih.gov/pubmed/36464726
http://dx.doi.org/10.1007/s11481-022-10054-7
_version_ 1784846589014048768
author Shen, Liang
Chen, Dan-yang
Lou, Qian-qian
Cao, Peng
Hu, Rui
Jin, Yan
Wang, Di
Hu, Shan-shan
author_facet Shen, Liang
Chen, Dan-yang
Lou, Qian-qian
Cao, Peng
Hu, Rui
Jin, Yan
Wang, Di
Hu, Shan-shan
author_sort Shen, Liang
collection PubMed
description Mechanically ventilated patients suffering critical illness are at high risk of developing neurocognitive impairments. Angiotensin type 2 receptor (AGTR2) has been demonstrated to be anti-inflammatory and neuroprotective. The present study thus aimed to investigate whether AGTR2 can alleviate cerebral dysfunction in mice subjected to cochallenge with lipopolysaccharide (LPS) and mechanical ventilation (MV), and to reveal the underlying mechanism. We utilized a mice model that received a single injection of LPS (1 mg/kg, intraperitoneally) followed 2 h later by MV (10 ml/kg, lasting for 2 h). Pretreatment with the AGTR2 pharmacological agonist C21 (0.03, 0.3, and 3 mg/kg, intraperitoneally, once daily, lasting for 10 days). Locomotor activity and behavioral deficits were evaluated 24 h post-MV by open-field and fear-condition tests. Brain hippocampus and prefrontal cortex tissues were collected for immunofluorescence staining and western blotting to evaluate the resulting impacts on microglia, including morphological traits, functional markers, synaptic engulfment, superoxide production, and signaling molecules. Compared with vehicle-control, pre-administrated C21 reduced the branch endpoints and length of microglia processes in a dose-dependent manner in mice subjected to LPS/MV. The neuroprotective effect of AGTR2 was behaviorally confirmed by the improvement of memory decline in LPS/MV-treated mice following C21 pretreatment. In addition to morphological alterations, C21 reduced microglial functional markers and reduced microglial-dendrite contact and microglial engulfment of synaptic protein markers. In terms of the underlying molecular mechanism, AGTR2 stimulation by C21 leads to activation of protein phosphatase 2A, which subsequently mitigates microglial PKCδ and NF-κB activation, and inhibites NOX2-derived ROS production. The AGTR2 agonist C21 alleviates behavioral deficits in those mice subjected to LPS/MV, via mechanisms that involve reactive microglia and abnormal synaptic plasticity in NOX2-derived ROS and the PKCδ-NFκB pathway. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-022-10054-7.
format Online
Article
Text
id pubmed-9734469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-97344692022-12-12 Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines Shen, Liang Chen, Dan-yang Lou, Qian-qian Cao, Peng Hu, Rui Jin, Yan Wang, Di Hu, Shan-shan J Neuroimmune Pharmacol Original Article Mechanically ventilated patients suffering critical illness are at high risk of developing neurocognitive impairments. Angiotensin type 2 receptor (AGTR2) has been demonstrated to be anti-inflammatory and neuroprotective. The present study thus aimed to investigate whether AGTR2 can alleviate cerebral dysfunction in mice subjected to cochallenge with lipopolysaccharide (LPS) and mechanical ventilation (MV), and to reveal the underlying mechanism. We utilized a mice model that received a single injection of LPS (1 mg/kg, intraperitoneally) followed 2 h later by MV (10 ml/kg, lasting for 2 h). Pretreatment with the AGTR2 pharmacological agonist C21 (0.03, 0.3, and 3 mg/kg, intraperitoneally, once daily, lasting for 10 days). Locomotor activity and behavioral deficits were evaluated 24 h post-MV by open-field and fear-condition tests. Brain hippocampus and prefrontal cortex tissues were collected for immunofluorescence staining and western blotting to evaluate the resulting impacts on microglia, including morphological traits, functional markers, synaptic engulfment, superoxide production, and signaling molecules. Compared with vehicle-control, pre-administrated C21 reduced the branch endpoints and length of microglia processes in a dose-dependent manner in mice subjected to LPS/MV. The neuroprotective effect of AGTR2 was behaviorally confirmed by the improvement of memory decline in LPS/MV-treated mice following C21 pretreatment. In addition to morphological alterations, C21 reduced microglial functional markers and reduced microglial-dendrite contact and microglial engulfment of synaptic protein markers. In terms of the underlying molecular mechanism, AGTR2 stimulation by C21 leads to activation of protein phosphatase 2A, which subsequently mitigates microglial PKCδ and NF-κB activation, and inhibites NOX2-derived ROS production. The AGTR2 agonist C21 alleviates behavioral deficits in those mice subjected to LPS/MV, via mechanisms that involve reactive microglia and abnormal synaptic plasticity in NOX2-derived ROS and the PKCδ-NFκB pathway. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11481-022-10054-7. Springer US 2022-12-05 /pmc/articles/PMC9734469/ /pubmed/36464726 http://dx.doi.org/10.1007/s11481-022-10054-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Shen, Liang
Chen, Dan-yang
Lou, Qian-qian
Cao, Peng
Hu, Rui
Jin, Yan
Wang, Di
Hu, Shan-shan
Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title_full Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title_fullStr Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title_full_unstemmed Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title_short Angiotensin Type 2 Receptor Pharmacological Agonist Relieves Neurocognitive Deficits via Reducing Neuroinflammation and Microglial Engulfment of Dendritic Spines
title_sort angiotensin type 2 receptor pharmacological agonist relieves neurocognitive deficits via reducing neuroinflammation and microglial engulfment of dendritic spines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734469/
https://www.ncbi.nlm.nih.gov/pubmed/36464726
http://dx.doi.org/10.1007/s11481-022-10054-7
work_keys_str_mv AT shenliang angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT chendanyang angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT louqianqian angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT caopeng angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT hurui angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT jinyan angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT wangdi angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines
AT hushanshan angiotensintype2receptorpharmacologicalagonistrelievesneurocognitivedeficitsviareducingneuroinflammationandmicroglialengulfmentofdendriticspines